B2M and hepatocellular carcinoma: The downregulation of B2M in LC4 cells mirrors what has been observed in clinical HCC cases, where loss of antigen presentation is associated with resistance to immune checkpoint inhibitors, such as PD-1/PD-L1 therapies [41,42].